TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06060613: Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Sponsor: Obsidian Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 254 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06060613 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06060613 Rescue Dossier →